Efficacy and safety of ibandronate given by intravenous injection once every 3 months
- 31 May 2004
- Vol. 34 (5) , 881-889
- https://doi.org/10.1016/j.bone.2004.01.007
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With RisedronateJournal of Bone and Mineral Research, 2003
- Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive AgentsJournal of Clinical Endocrinology & Metabolism, 2002
- Effect of Risedronate on the Risk of Hip Fracture in Elderly WomenNew England Journal of Medicine, 2001
- Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone DensityJournal of Clinical Endocrinology & Metabolism, 2000
- Alendronate gastric ulcersAlimentary Pharmacology & Therapeutics, 1999
- IbandronateDrugs, 1999
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996
- Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionJournal of Bone and Mineral Research, 1996
- Adverse Effects of BisphosphonatesDrug Safety, 1996
- RENAL FAILURE ASSOCIATED WITH INTRAVENOUS DIPHOSPHONATESThe Lancet, 1983